The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; GlaxoSmithKline; Hookipa Biotech; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; TERUMO
 
Florian Lordick
Honoraria - Art Tempi; Astellas Pharma; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Falk Foundation; Incyte; Lilly; Medscape; Medupdate; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER; Streamedup!
Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daichi Sankyo; Merck Sharp & Dohme; PAGE
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly
 
Peter C. Enzinger
Consulting or Advisory Role - ALX Oncology; Amgen; Arcus Biosciences; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Celgene; Chimeric Therapeutics; Chimeric Therapeutics; Coherus Biosciences; Daiichi Sankyo; Eisai; IDEAYA Biosciences; Legend Biotech; Legend Biotech; Lilly; Loxo; loxo; Merck; Novartis; Oncolys BioPharma; Ono Pharmaceutical; Regeneron; Sanofi; SERVIER; Taiho Oncology; Taiho Pharmaceutical; Takeda; Takeda; Turning Point Therapeutics; Turning Point Therapeutics; Xencor; Xencor; Zymeworks
 
David H. Ilson
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Lilly/ImClone; Macrogenics; Merck; Roche/Genentech; Taiho Pharmaceutical
 
Manish A. Shah
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Oncolys BioPharma (Inst)
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; CPPC; Hengrui Pharm; Hutchison MediPharma; Innovent Biologics; Junshi Pharmaceuticals; Keymed Biosience; Merck Serono; MSD; QiLu Pharmaceutical; Roche
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Yi-Ping Hung
No Relationships to Disclose
 
Bozena Kukielka-Budny
No Relationships to Disclose
 
Pranob P. Bhattacharya
Employment - Astellas Pharma
 
Maria Matsangou
Employment - Astellas Pharma
 
Ran Li
Employment - Astellas Pharma
 
Diarmuid Martin Moran
Employment - Astellas Pharma
 
Radhika Ranganath
Employment - Astellas Pharma
 
Rupesh Pophale
Employment - Astellas Pharma
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; Amgen; Arcus Biosciences; Astellas Pharma; BeiGene; BeiGene; Bristol-Myers Squibb; Geneos; Gilead Sciences; Insys Therapeutics; Merck; Novartis; SERVIER; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly